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Abstract Cushing’s syndrome due to ectopic adrenocorti-
cotropic hormone production from adrenal medullary
lesions has occasionally been described. We retrospectively
reviewed all 164 cases of Cushing’s syndrome and 77 cases
of pheochromocytomas during 10 years. Of all cases with
Cushing’s syndrome, only two cases (1.2 %) were due to
ectopic adrenocorticotropic hormone production from
adrenal medullary lesions (one case of pheochromocytoma
and one case of adrenal medullary hyperplasia). Of all
pheochromocytomas only the above-mentioned case
(1.3 %) also gave rise to an ectopic adrenocorticotropic
hormone syndrome. The clinical presentation of
adrenocorticotropic hormone-secreting pheochromocytoma
and adrenal medullary hyperplasia can be anything from
mild to dramatic. These are rare conditions important to
bear in mind in the workup of a patient with Cushing’s
syndrome or with pheochromocytoma. The identiﬁcation of
ectopic adrenocorticotropic hormone secretion from adrenal
medullary lesions can be life-saving.
Keywords Cushing ● Ectopic ● Adrenal medullary
hyperplasia ● Pheochromocytoma
Introduction
Cushing’s syndrome caused by endogenous hypercortiso-
lism is a rare disorder with an incidence of about 0.2–5.0
cases per million population per year and a prevalence of
about 39–79 per million [1]. Endogenous Cushing’s syn-
drome is divided into adrenocorticotropic hormone
(ACTH)-dependent, mainly pituitary tumors and ectopic
ACTH production, or ACTH-independent, mainly adreno-
cortical tumor/hyperplasia and adrenocortical cancer [1].
Pheochromocytomas are also rare but in certain groups such
as in unselected patients with adrenal incidentaloma
0.6–1.4 % are affected [2, 3]. Both Cushing’s syndrome and
pheochromocytoma are serious conditions, which can be
fatal if not diagnosed and/or managed appropriately [1, 4].
The combination of both hypercortisolism and increased
catecholamine secretion has an even higher fatality potential
and has infrequently been reported in the literature in
ectopic ACTH syndrome due to pheochromocytoma [5–8].
The aims of the present study were to determine in a
large cohort with Cushing’s syndrome from a single center
the frequency of hypercortisolism due to ACTH secretion
from adrenal medullary lesions and how frequently pheo-
chromocytomas result in ectopic ACTH syndrome. More-
over, we also wanted to characterize the identiﬁed cases.
Subjects and methods
This retrospective study was conducted at the Department
of Endocrinology, Metabolism and Diabetes, Karolinska
University Hospital, Stockholm, Sweden. All patients with
an International Classiﬁcation of Diseases version 10 (ICD-
10) code of E275 (adrenomedullary hyperfunction), C741
(malignant neoplasm of medulla of adrenal gland), E240
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(pituitary-dependent Cushing’s disease), E243 (ectopic
ACTH syndrome), E248 (other Cushing’s syndrome), and/
or E249 (Cushing’s syndrome, unspeciﬁed) and who had
attended the out-patient clinic between June 2005 and June
2015 were eligible for inclusion. All the electronic medical
ﬁles of the patients were reviewed manually and those
where the ﬁnal diagnosis did not correspond to the previous
mentioned ICD-10 code(s) were subsequently excluded. All
specialist out-patient visits in Sweden are coded with ICD-
10 codes by the attending physician and are thereafter
stored in both local and national databases [9]. The clinical,
biochemical, and histological data of patients with Cush-
ing’s syndrome due to ectopic ACTH secretion from the
adrenal medulla were recorded in detail.
Cushing’s syndrome was diagnosed if at least two bio-
chemical tests, 1 mg overnight dexamethasone suppression
test, 24 h urine cortisol and midnight serum cortisol, were
clearly abnormal, together with a clinical picture of Cushing’s
syndrome [3]. ACTH-independent (adrenal) Cushing’s syn-
drome was diagnosed if the ACTH was decreased, otherwise
an ACTH-dependent Cushing’s syndrome was presumed. To
discriminate between pituitary or ectopic ACTH production,
magnetic resonance imaging (MRI) of the pituitary gland,
high-dose dexamethasone suppression test, and/or bilateral
inferior petrosal sinus sampling were performed [1].
Plasma ACTH was measured on an advantage automatic
immune analyzer (Nichols Institute Diagnostics, San
Clemente, CA, USA), serum cortisol using electrochemical
luminescence Modular E (Roche Diagnostics, Mannheim,
Germany), urinary cortisol and plasma metanephrine and
normetanephrine using liquid chromatography-tandem mass
spectrometry (Sigma-Aldrich, St. Louis, MO, USA), and
plasma chromogranin A using radioimmunoassay (Malmö,
Sweden).
The Regional Ethical Review Board in Stockholm,
Sweden, approved the study.
Results
In total 164 cases of Cushing’s syndrome were found of
which 61.6 % owed to excess ACTH production from a
pituitary tumor (Cushing’s disease), 32.3 % to an adreno-
cortical tumor/hyperplasia, and 6.1 % to ectopic ACTH
syndrome (Table 1). Of the 10 patients with ectopic ACTH
syndrome, 1 (10 %) was due to adrenal medullary hyper-
plasia and 1 (10 %) due to a pheochromocytoma. Thus,
20 % of all ectopic Cushing’s syndrome, but only 2 of 164
cases (1.2 %) of all Cushing’s syndromes, were the result of
ACTH-secreting adrenal medullary lesions.
In total 77 cases of pheochromocytomas had been
diagnosed of which the previously mentioned patient
(1.3 %) had also given rise to an ectopic ACTH syndrome.
Case 1
A 50-year-old woman presented to the emergency depart-
ment (ED) due to gastroenteritis followed by palpitations,
headache, and anxiety. She had a previous history of
headaches, tremor, chest pain, palpitations, anxiety, and
perspiration for at least 3 years and had had both a Coronary
Care Unit admission and a neurology out-patient review for
these symptoms. There was no family history of Cushing’s
syndrome or pheochromocytoma. An increased blood
pressure of 160/105 was found with slightly low plasma
potassium (3.2 mmol/L). Bisoprolol 2.5 mg was initiated,
but as the patient did not feel well on this medication a
change to amlodipine 5 mg daily was made with a plan of
follow-up with the general practitioner. She presented again
to ED a month later with decreased appetite, weight loss of
12 kg during the last month (from 65 to 53 kg), fatigue,
muscle weakness, anxiety, hirsutism, increased urine out-
put, blurry vision, and increased palpitation and tremor.
Increased plasma glucose levels and severely low potassium
were found together with a metabolic alkalosis (Table 2).
She was admitted with potassium replacement and insulin
treatment. Following days serum cortisol was measured at
different times and they were all >2000 nmol/L and urinary
cortisol level was very high. Urinary steroid proﬁle
demonstrated increased secretion of cortisol metabolites and
also androgens consistent with Cushing’s syndrome but no
precursor steroids that could indicate an adrenocortical
cancer. Her appearance was not typical for Cushing’s syn-
drome but she looked unhealthy with muscle wasting and
rapid weight loss (Fig. 1, upper panel). A computed
Table 1 Causes of endogenous Cushing’s syndrome in 164 cases atten
ded out-patient clinic during 10 years at the Karolinska University Hospital
ACTH-dependent, n 111 (67.7 %)
Cushing’s disease, n 101 (61.6 %)
Ectopic ACTH syndrome, n 10 (6.1 %)
Small cell lung cancer, n 3 (30 %)
Bronchial carcinoid, n 2 (20 %)
Endocrine pancreas tumor, n 1 (10 %)
Cervix cancer, n 1 (10 %)
Pregnancy-associated, n 1 (10 %)
Pheochromocytoma, n 1 (10 %)
Adrenal medullar hyperplasia, n 1 (10 %)
Unknown, n 1 (10 %)
ACTH-independent 53 (32.3 %)
Adrenocortal adenoma/hyperplasia 47 (28.7%)
Adrenocortical cancer 6 (3.6 %)
Total 164 (100 %) 10 (100 %)
Note Special focus has been given to ectopic ACTH syndrome
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tomography (CT) scan identiﬁed a 3.5-cm large mass on the
left adrenal and radiological bilateral adrenal hyperplasia
(Fig. 2, upper panel), while the abdomen, thorax, and MRI
of the pituitary were normal. Subsequent plasma ACTH was
high, plasma metanephrine was almost three times upper
reference limit, while plasma normetanephrine was just
above the upper reference limit (Table 2). Alfa blocker and
spironolactone were added and she underwent an uncom-
plicated left adrenalectomy 3 weeks after the admission
under the cover of hydrocortisone infusion and later oral
hydrocortisone. After surgery, the doses of insulin and
potassium were decreased dramatically and she was dis-
charged 4 weeks after the admission much improved. His-
tology showed a radically extirpated 3.5 × 2.2 × 1.5 cm
large pheochromocytoma displaying multifocal evidence
vascular invasion. The majority (75–100 %) of tumor cells
expressed ACTH and the Ki67-index was 7 %. The sur-
rounding adrenocortical tissue was hyperplastic and nega-
tive for ACTH immunoreactivity (Fig. 3, upper panel).
Since the current WHO criteria for malignancy (presence of
metastases) could not be fulﬁlled, the tumor was considered
benign with potential of malignant behavior and so close
follow-up was recommended. Two months post surgery she
was in a good shape, had regained her previous weight, and
all her symptoms had disappeared (Fig. 1, lower panel).
During the next 4 months all medications were weaned off
and she had started doing exercise on a regular basis. She
claimed feeling better than she had done in many years.
Three years later, there was still no biochemical or radi-
ologic signs of recurrence.
Case 2
A 44-year-old woman with levothyroxin-treated hypothyr-
oidism was referred to the out-patient clinic from her general
practitioner with the question of Cushing’s syndrome. The
last few years she had suffered from depression, fatigue,
insomnia, concentration difﬁculties, easy bruising, proximal
muscle weakness, and muscle and joint pain, as well as
amenorrhea. Her face had got slightly round and red. Fat
deposition at the supraclavicular fossa, between the shoulders
and abdomen was noted. Acne and perspiration were present
but no hirsutism. Physical ﬁtness had decreased but she was
still jogging or cycling a few times a week to keep her weight
stable. She had acquired stress fractures to her foot in con-
nection with running. The symptoms had aggravated sig-
niﬁcantly during the last 3 months before referral. The patient
had been on sick leave intermittently during the last years.
There was no family history of Cushing’s syndrome or
pheochromocytoma. Blood pressure was 130/85. Serum and
urine cortisol were increased, while plasma ACTH was only
marginally elevated (Table 2). MRI of the pituitary was
normal and sinus petrosus sampling could not show an
increase in ACTH after corticotropin-releasing hormone
Table 2 Biochemical results
pre-adrenalectomy and post-
adrenalectomy in two cases with
ectopic ACTH syndrome due to
pheochromocytoma (Case 1) or
adrenal medullary hyperplasia
(Case 2)











P-potassium (nmol/L) 2.4 3.9 4.0 4.8 3.5–4.4
P-glucose (mmol/L) 33
(random)
4.3 5.0 5.4 4.0–6.0
(fasting)
Base excess (mmol/L) 14.8 −3–3
pH 7.57 7.35–7.45
S-cortisol (nmol/L) 8 am >2000 <15* 671 <15 200–800
Midnight >2000 462 <50
U-cortisol (nmol/24 h) 22400 346 40–170





P-ACTH (pmol/L) 8 am 149 4 12 <0.5 (2.0–10)
fP-metanephrine (nmol/L) 1.1 0.2 <0.2 <0.2 <0.3
fP-normetanephrine (nmol/L) 0.7 <0.2 <0.2 0.4 <0.6
fP-chromogranin A (nmol/L) 10.4 0.8 1.8 <3.0
P-renin (mU/L) 40 2.8–40
P-aldosterone (pmol/L) 231 <650
P plasma, S serum, U urine, DST dexamethasone suppression test, f fasting. *505 nmol/L 6 months later
without any medication
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(CRH) stimulation. Low-dose and high-dose dexamethasone
suppression test did not suppress cortisol levels, but instead
paradoxical increases were seen. CT of the neck, thorax, and
abdomen revealed a heterogeneous 5-cm large left adrenal
mass (Fig. 2, lower panel). Plasma metanephrine, normeta-
nephrine, and chromogranin A were all normal. Urine steroid
proﬁle demonstrated increased cortisol metabolites, low
androgens, and no precursor steroids. During surgery when
the left adrenal was mobilized, blood pressure increased to
250/120 and i.v. alpha blockade and adenosine were admi-
nistered due to suspicion of a pheochromocytoma. After
surgery the patient needed norepinephrine infusion on top of
the hydrocortisone infusion. Histology revealed a radically
extirpated adrenal mass presenting as nodular adrenocortical
hyperplasia together with adrenal medullar hyperplasia, in
which 10% of the adrenal medullary cells expressed ACTH
but the Ki67-index was low (<1%) (Fig. 3, lower panel). In
contrast, there was no ACTH expression in the nodular
Fig. 1 50-year-old women
(Case 1) with ectopic ACTH
syndrome due to a
pheochromocytoma with a rapid
weight loss, muscle wasting,
hypokalemia, high glucose
levels, and hirsutism (upper
panel). Two months after
surgery she had returned to her
previous weight and her
symptoms had disappeared
(lower panel)
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adrenocortical hyperplasia tissue. After surgery the patient felt
better and the hydrocortisone supplementation was slowly
lowered. However, at the last follow-up 2.5 years later serum
cortisol and plasma ACTH were still suppressed and she still
needed hydrocortisone replacement, felt tired, and was
working only 50%.
Discussion
Only 1.2% of all patients with Cushing’s syndrome were
due to ACTH secretion from a pheochromocytoma or an
adrenal medullary hyperplasia, and only 1.3 % of all
pheochromocytomas identiﬁed also resulted in an ectopic
ACTH syndrome. This is similar to a study that identiﬁed
that 1 % of all pheochromocytomas also had an ectopic
hormone secretion, of which 50% had excess cortisol
secretion [6]. Of all our cases with Cushing’s syndrome,
61.6 % were due to a pituitary tumor, 32.3 % due to an
adrenocortical tumor/hyperplasia (3.6 % adrenocortical can-
cer), and 6.1% due to ectopic ACTH syndrome, which is in
accordance with a recent review [1]. However, the frequency
of Cushing’s syndrome as a result of ACTH secretion from a
pheochromocytoma or adrenal medullary hyperplasia is
unclear from the literature. It has been claimed that 2.5–5%
of all ectopic ACTH syndromes is caused by a pheochro-
mocytoma [5, 10], while we found ACTH secretion in 10%
from medullary cells in a pheochromocytoma and 10% from
adrenal medullary hyperplasia. The differences may be the
result of different selection biases and/or chance in these rare
cases. Anyhow, an under-registration can easily occur. Most
patients with ectopic ACTH syndrome are primarily seen by
oncologists and as these patients are very unwell and maybe
treated with glucocorticoids, makes it a challenge to suspect
and detect Cushing’s syndrome. Moreover, our endocrine
service may only have seen some patients as in-patient
consults or been consulted on telephone. Thus, these would
not been registered in our out-patient database, which may
explain some of the differences. In some cases of
pheochromocytoma-associated ACTH-dependent Cushing’s
syndrome, the ectopically secreted hormone is CRH, with
ACTH being secreted by pituitary hyperplasia [8]. Since pre-
operative petrosal sinus sampling/CRH assays and post-
operative CRH immunostaining are not routinely performed
when pheochromocytoma-associated ACTH-dependent
Cushing’s syndrome is suspected, some published cases
could have been misclassiﬁed as ACTH-secreting instead of
CRH-secreting.
Adrenal medullary hyperplasia can be viewed as a pre-
cursor of a pheochromocytoma and have been associated
with familiar pheochromocytomas [11]. The distinction
between adrenal medullary hyperplasia and pheochromo-
cytoma is mainly based on the size of the lesion with <1 cm
considered to represent hyperplasia, provided it grossly, and
microscopically resembles the rest of the medulla [12].
Adrenal medullary hyperplasia is sometimes considered a
benign lesion, which does not overproduce catecholamines
[13]; however, others have reported mild increased cate-
cholamine secretion and symptoms and recommend surgery
with a similar preoperative preparation as with pheochro-
mocytomas [14]. To the best of our knowledge, our case of
adrenal medullary hyperplasia is the ﬁrst reported with a
concomitant ACTH secretion. The two cases describe the
large spectrum of ectopic ACTH syndrome. The ﬁrst
case had in hindsight several years of symptoms from
increased catecholamine production; however, severe
Fig. 2 CT with contrast from Case 1 demonstrating a left-sided 3.5 ×
4.5 cm large adrenal tumor with peripheral contrast enhancement and
septa-like structures in addition to bilateral adrenal hyperplasia (upper
panel). CT without contrast from Case 2 showing a left-sided 3.5 ×
4.5 × 5 cm large heterogeneous adrenal mass (lower panel)
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hypercortisolism with hypokalemia developed in just over a
month. Ectopic ACTH syndrome can develop very rapidly
and too quickly to develop the classical signs of Cushing’s
syndrome. Under such circumstances a bilateral adrena-
lectomy can be a life-preserving emergency therapy [15]. In
contrast, the second case had a slower progression of her
Cushing’s syndrome developing over several years,
although she got worse the last few months before diag-
nosis. In this case, no biochemical evidence of a pheo-
chromocytoma was found pre-operatively, but signs of
catecholamine hyper-secretion were found during surgery.
Interestingly, this case demonstrated an ACTH upregulation
with paradoxical response to dexamethasone similar to what
has been recently described by Sakuma et al. [16]. They
presented a case where both ACTH and catecholamine
secretion were upregulated by dexamethasone. With
immunohistological and in vitro studies it was indicated that
hypomethylation of the proopiomelanocortin promoter may
be responsible for the paradoxical ACTH response to dex-
amethasone. Also post-operatively there were differences
between the cases with the ﬁrst recovering quickly, while
the second had not recovered fully after almost 3 years. The
second patient is still suffering from impaired quality of life
and mental fatigue, a common complication in patients with
Cushing’s syndrome despite remission [17].
The clinical characteristics and pathological ﬁndings of
these two cases with ectopic ACTH production compared to
other pheochromocytomas without ACTH production were
quite evident with signs and symptoms of increased cortisol
secretion, even though they did not both present with all
classic signs such as hypokalemia, hyperglycemia (even
though also pheochromocytomas can give hyperglycemia
but normally not to the same degree), easy bruising, chan-
ges in fat distribution, and so on. Other signs such as
hypertension are often found in both condition but hyper-
tensive crisis is more associated with increased catechola-
mine levels similar to tachycardia and headaches. On the
other hand, suspecting ectopic ACTH production from a
pheochromocytoma or an adrenal medullary hyperplasia
can be more challenging, since the catecholamine-related
symptoms and signs may easily be obscured by the cortisol-
related ones. To overcome some of these challenges and
potential serious consequences, we recommend analyzing
plasma metanephrines and evaluation for hypercortisolism
in all adrenal tumors, irrespective if an adrenocortical or
medullar tumor is suspected. However, adrenal medullary
hyperplasia may still be undiagnosed illustrated by our
second case.
The inherent limitations of all retrospective studies, in
particularly that of ascertainment bias, are also present in
this study. Moreover, not all biochemical and genetic tests
together with imaging, which in hindsight would have been
interesting, were done.











Fig. 3 Photomicrographs of the adrenal medullary lesions from Case 1
(upper panel) and Case 2 (lower panel), respectively. In Case 1, the
pheochromocytoma is clearly positive for chromogranin A and ACTH,
whereas the surrounding adrenocortical hyperplasia (secondary to the
ACTH production) is negative. In Case 2, the photomicrographs
represent the adrenal medullary hyperplasia with focal ACTH pro-
duction. H&E hematoxylin-eosin staining, PCC pheochromocytoma,
ACH adrenocortical hyperplasia, AMH adrenal medullary hyperplasia
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Conclusion
The clinical presentation of ACTH-secreting pheochromo-
cytomas and adrenal medullary hyperplasia can be anything
from mild to dramatic. They are rare conditions but
important to bear in mind in the workup of a patient with
Cushing’s syndrome or with pheochromocytoma. The
identiﬁcation of ectopic ACTH production from adrenal
medullary lesions can be life-saving.
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